

# Pharmaceutical Pipeline – Key Events in 2019\*

<b>Potential Approvals US/EU</b>	ERLEADA™ (apalutamide) – Non-metastatic prostate cancer (EU) ✓	<b>Potential Clinical Data Presentations</b>	INVOKANA® – Diabetic Nephropathy (CREDESCENCE)	
	Erdafitinib – Urothelial cancer (US)		STELARA® – Ulcerative Colitis (UNIFI)	
	Esketamine Nasal Spray – Treatment-resistant depression (US / EU)		Rilpivirine long Acting Maintenance – HIV (ATLAS / FLAIR)	
	STELARA® – Ulcerative Colitis (US / EU)		<b>Phase 3</b>	TREMFYA® – Psoriatic Arthritis (DISCOVER 1 & 2)
	OPSUMIT® – Chronic thromboembolic pulmonary hypertension (EU)			ERLEADA™ (apalutamide) – Hormone-naïve prostate cancer (TITAN)
	XARELTO® – VTE prevention medically ill patients (US)			esketamine – Major Depressive Disorder at Imminent Risk for Suicide (SUI3001/3002)
	IMBRUVICA® – Frontline CLL combo w/obinutuzumab (US / EU) – Waldenström's Macroglobulinemia in combo w/rituximab (EU)		<b>Potential Clinical Data Presentations</b>	DARZALEX® – Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (COLUMBA) – Frontline Multiple Myeloma transplant (CASSOPEIA)
	TREMFYA® – Psoriasis Patient-Controlled Injector (US)			UPTRAVI® – Pulmonary arterial hypertension IV (AC-065A309)
	DARZALEX® – Frontline Multiple Myeloma transplant ineligible in combo w/ lenalidomide and low dose dexamethasone (MAIA) (US)			DARZALEX® – Subcutaneous formulation in combination with standard multiple myeloma treatments (PLEIADES)
<b>Planned Submissions US/EU</b>	Rilpivirine long acting maintenance – HIV (US / EU)	<b>Potential Clinical Data Presentations</b>	HIV Vaccine – HIV (ASCENT)	
	Esketamine Nasal Spray – Major Depressive Disorder at Imminent Risk for Suicide (US)		<b>Phase 2</b>	Niraparib – L3 Metastatic Castration-Resistant Prostate Cancer (GALAHAD)
	DARZALEX® – Frontline Multiple Myeloma transplant ineligible in combo w/ lenalidomide and low dose dexamethasone (MAIA) (US / EU) – Frontline Multiple Myeloma transplant (CASSOPEIA) (US / EU) – Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (US / EU)			
	ERLEADA™ (apalutamide) – Hormone naive prostate cancer (TITAN) (US / EU)			
	INVOKANA® – Diabetic nephropathy (US / EU)			
	TREMFYA® – Psoriatic Arthritis (US / EU)			
	UPTRAVI® – Pulmonary arterial hypertension IV (US / EU)			

✓ = Achieved

\* This information is accurate as of January 22, 2019 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.